Newly formed company to develop urology drugs

"Robotic surgery has some major advantages. One that rises to the top is that your magnification is anywhere from 10x-15x higher," according to Laurence S. Baskin, MD.

In this episode, Julia Beth Finkelstein, MD, MPH, CPPS, discusses what she and her co-authors learned from a recent study evaluating the use of telemedicine for pediatric post-op visits.

The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria.

FDA new drug application filing expected by the end of 2021.

Join Urology Times and Contemporary Pediatrics for a discussion about controversies over circumcision and its implications.

The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).